review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | Christine Maric-Bilkan | |
P2860 | cites work | Obesity-related renal damage: changing diet to avoid progression | Q85031771 |
Effects of genetic obesity on renal structure and function in the Zucker rat | Q93634728 | ||
Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies | Q93634731 | ||
Obesity and Risk for Chronic Renal Failure | Q22241459 | ||
Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function | Q24320075 | ||
Adiponectin regulates albuminuria and podocyte function in mice | Q24324384 | ||
Association between body mass index and CKD in apparently healthy men | Q28192932 | ||
Prevalence of overweight and obesity in the United States, 1999-2004 | Q28305811 | ||
Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin | Q28588020 | ||
Prevalence and trends in obesity among US adults, 1999-2008 | Q29547759 | ||
Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010 | Q29555853 | ||
Prevalence of chronic kidney disease in the United States | Q29614191 | ||
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001 | Q29614193 | ||
Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010 | Q29614504 | ||
Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. | Q33738003 | ||
The renal vascular response to diabetes | Q33917570 | ||
Tubular reabsorption and diabetes-induced glomerular hyperfiltration. | Q34057976 | ||
Obesity-associated hypertension and kidney disease | Q34177580 | ||
The kidney, hypertension, and obesity | Q34182175 | ||
Obesity-related glomerulopathy: an emerging epidemic | Q34190647 | ||
Impact of the obesity epidemic on hypertension and renal disease. | Q34226559 | ||
The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis | Q34252401 | ||
Sympathetic nervous system and insulin resistance: from obesity to diabetes | Q34448148 | ||
Glomerular sclerosis in patients with massive obesity | Q70055629 | ||
Clinical factors associated with urinary albumin excretion in type II diabetes | Q72289158 | ||
Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes | Q73322138 | ||
Role of angiotensin II in diabetic nephropathy | Q73745588 | ||
Functional and structural changes in the kidney in the early stages of obesity | Q73928010 | ||
Prevention of obesity-linked renal disease: age-dependent effects of dietary food restriction | Q74351905 | ||
Obesity and target organ damage: the kidney | Q78588988 | ||
Body mass index and the risk of development of end-stage renal disease in a screened cohort | Q79933214 | ||
Obesity-related glomerulopathy | Q81096849 | ||
Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy | Q81349144 | ||
Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption | Q81630363 | ||
Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial | Q84791989 | ||
Mechanisms of obesity-associated cardiovascular and renal disease | Q34870994 | ||
Diabetes and nephropathy | Q35108195 | ||
Hyperfiltration and glomerulosclerosis | Q35110865 | ||
Kidney function in early diabetes: the tubular hypothesis of glomerular filtration | Q35600696 | ||
Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator | Q35611125 | ||
Is obesity a major cause of chronic kidney disease? | Q35632565 | ||
The kidney in type 2 diabetes therapy | Q35760302 | ||
Inflammation and oxidative stress in obesity-related glomerulopathy | Q35904102 | ||
Obesity prevalence in the United States--up, down, or sideways? | Q35936302 | ||
Interaction of haemodynamic and metabolic pathways in the genesis of diabetic nephropathy | Q36278532 | ||
Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study | Q36432084 | ||
Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. | Q36443224 | ||
Novel roles of intracrine angiotensin II and signalling mechanisms in kidney cells | Q36513492 | ||
Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults | Q36566370 | ||
Obesity, proteinuria and progression of renal failure | Q36568186 | ||
Obesity paradox in patients on maintenance dialysis | Q36575244 | ||
Leptin and renal fibrosis | Q36575277 | ||
AT(1) receptors and control of blood pressure: the kidney and more... | Q36702347 | ||
Health risks associated with overweight and obesity | Q36742564 | ||
Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study | Q36865845 | ||
Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade | Q36910471 | ||
Association between obesity and kidney disease: a systematic review and meta-analysis | Q36967756 | ||
Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study | Q37054973 | ||
Adverse renal consequences of obesity | Q37072213 | ||
Obesity, diabetes, and chronic kidney disease | Q37078515 | ||
Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD | Q37221285 | ||
The role of inflammatory cytokines in diabetes and its complications | Q37232605 | ||
Insights into the regulation of renal hemodynamic function in diabetic mellitus | Q37320171 | ||
Impact of obesity on renal structure and function in the presence and absence of hypertension: evidence from melanocortin-4 receptor-deficient mice. | Q37337571 | ||
The glomerular filter: an imperfect barrier is required for perfect renal function | Q37498218 | ||
Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria | Q37590634 | ||
Obesity Related Kidney Disease | Q37808494 | ||
Is there an obesity-metabolic syndrome related glomerulopathy? | Q37810756 | ||
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management | Q37827620 | ||
Management of blood pressure in patients with diabetes | Q37869806 | ||
The goal of blood pressure control for prevention of early diabetic microvascular complications | Q37869820 | ||
Systematic kidney disease management in a population with diabetes mellitus: turning the tide of kidney failure | Q37896378 | ||
Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients | Q38345536 | ||
The metabolic syndrome and chronic kidney disease in U.S. adults | Q38941738 | ||
Risk factors for microalbuminuria in black americans with newly diagnosed type 2 diabetes | Q39550781 | ||
Obesity-related hypertension: epidemiology, pathophysiology, and clinical management | Q39848035 | ||
Is obesity-related hypertension less of a cardiovascular risk? The Framingham Study | Q41210184 | ||
Control of renal hemodynamics in hyperglycemia: possible role of tubuloglomerular feedback | Q41479718 | ||
Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. | Q42088836 | ||
Lifestyle factors, obesity and the risk of chronic kidney disease | Q42171674 | ||
Effect of lipid reduction on the progression of renal disease: a meta-analysis | Q43514434 | ||
Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis | Q43720126 | ||
Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults | Q44041092 | ||
Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway | Q44111532 | ||
Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. | Q44201217 | ||
Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. | Q44248315 | ||
Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies | Q44293250 | ||
A central body fat distribution is related to renal function impairment, even in lean subjects | Q44383378 | ||
The effects of weight loss on renal function in patients with severe obesity | Q44449830 | ||
The disease burden associated with overweight and obesity | Q44817527 | ||
Early improvement in albuminuria in non-diabetic patients after Roux-en-Y bariatric surgery | Q44896182 | ||
Microalbuminuria and obesity: impact on cardiovascular disease and mortality | Q45145527 | ||
Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion | Q45168898 | ||
ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis | Q45197190 | ||
Leptin and lipid metabolism in chronic kidney failure | Q46160192 | ||
National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants | Q46179172 | ||
Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes | Q46696577 | ||
Body mass index and angiotensin-dependent control of the renal circulation in healthy humans | Q46802769 | ||
Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program | Q46873807 | ||
Body mass index and risk for end-stage renal disease | Q46876497 | ||
Activated macrophages down-regulate podocyte nephrin and podocin expression via stress-activated protein kinases | Q47333969 | ||
Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials | Q47442278 | ||
Glomerular hyperfiltration in the prediction of nephropathy in IDDM: a 10-year follow-up study. | Q50991798 | ||
Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. | Q53620233 | ||
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. | Q54656315 | ||
The epidemiology of obesity | Q57196005 | ||
Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries | Q57316172 | ||
Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial | Q57702534 | ||
Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice | Q58363469 | ||
Increasing Body Mass Index and Obesity in the Incident ESRD Population | Q60777261 | ||
Adenosine A(1) receptors determine glomerular hyperfiltration and the salt paradox in early streptozotocin diabetes mellitus | Q63384113 | ||
Incidence and precursors of hypertension in young adults: the Framingham Offspring Study | Q69038435 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | obesity | Q12174 |
P304 | page(s) | 59-74 | |
P577 | publication date | 2012-11-27 | |
P1433 | published in | Medical Clinics of North America | Q15761972 |
P1476 | title | Obesity and diabetic kidney disease | |
P478 | volume | 97 |
Q52804042 | A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. |
Q47574114 | A non-laboratory-based risk score for predicting diabetic kidney disease in Chinese patients with type 2 diabetes |
Q35042543 | Ancestral dichlorodiphenyltrichloroethane (DDT) exposure promotes epigenetic transgenerational inheritance of obesity |
Q37669821 | Assessing natural direct and indirect effects for a continuous exposure and a dichotomous outcome |
Q33864503 | Association between class III obesity (BMI of 40-59 kg/m2) and mortality: a pooled analysis of 20 prospective studies |
Q64965992 | Bariatric Surgery Modulates Urinary Levels of MicroRNAs Involved in the Regulation of Renal Function. |
Q92740795 | Body Mass Index and Tooth Loss: An Epidemiological Study in a Sample of Suburban South Indian Population |
Q47139307 | Chow fed UC Davis strain female Lepr fatty Zucker rats exhibit mild glucose intolerance, hypertriglyceridemia, and increased urine volume, all reduced by a Brown Norway strain chromosome 1 congenic donor region |
Q42872632 | Chronic kidney disease: the "perfect storm" of cardiometabolic risk illuminates genetic diathesis in cardiovascular disease |
Q88778182 | Clinical and Pathology Findings Associate Consistently with Larger Glomerular Volume |
Q55456375 | Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus. |
Q50100048 | Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). |
Q21284809 | Curcumin and diabetes: a systematic review |
Q26799427 | Diabetic Nephropathy without Diabetes |
Q35774087 | Diagnostic and prognostic utility of non-invasive imaging in diabetes management |
Q63430760 | Dietary intake of cod protein beneficially affects concentrations of urinary markers of kidney function and results in lower urinary loss of amino acids in obese Zucker fa/fa rats |
Q47387845 | Effect of bariatric surgery on diabetic nephropathy in obese type 2 diabetes patients in a retrospective 2-year study: A local pilot |
Q41034789 | Effect of synergistic interaction between abnormal adiposity-related metabolism and prediabetes on microalbuminuria in the general population |
Q33875634 | Effects of Na/K-ATPase and its ligands on bone marrow stromal cell differentiation |
Q90835854 | Effects of low skeletal muscle mass and sarcopenic obesity on albuminuria: a 7-year longitudinal study |
Q90118349 | Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial |
Q49334065 | Immunologic and endocrine functions of adipose tissue: implications for kidney disease |
Q36458435 | Impact of Lifestyle Modification on Diabetic Kidney Disease |
Q64939469 | Kidney Disease in Diabetes Mellitus: Cross-Linking between Hyperglycemia, Redox Imbalance and Inflammation. |
Q41557819 | Mast Cell and M1 Macrophage Infiltration and Local Pro-Inflammatory Factors Were Attenuated with Incretin-Based Therapies in Obesity-Related Glomerulopathy |
Q89584929 | Modern pharmacological treatment of obese patients |
Q33903763 | Nephropathy in youth and young adults with type 2 diabetes |
Q46593121 | Nicotine Enhances High-Fat Diet-Induced Oxidative Stress in the Kidney |
Q34367664 | Obesity in kidney disease: A heavyweight opponent |
Q38947055 | Obesity, weight change, and chronic kidney disease in patients with type 2 diabetes mellitus: A longitudinal study in Taiwan. |
Q36913776 | Obesity-associated oxidative stress: strategies finalized to improve redox state |
Q40366908 | Overexpression of transcription factor FOXC2 in cultured human podocytes upregulates injury markers and increases motility |
Q90458884 | Podocyte-specific deletion of tubular sclerosis complex 2 promotes focal segmental glomerulosclerosis and progressive renal failure |
Q36138508 | Renoprotective Effects of Atorvastatin in Diabetic Mice: Downregulation of RhoA and Upregulation of Akt/GSK3. |
Q91984454 | Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects |
Q35376705 | Shock wave lithotripsy does not impair renal function in a Swine model of metabolic syndrome |
Q37280851 | Short-term changes after a weight reduction intervention in advanced diabetic nephropathy |
Q36084240 | The Age-Specific Association of Waist Circumference and Risk of Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus in Shandong, China |
Q58611695 | The Relationship between Generalized and Abdominal Obesity with Diabetic Kidney Disease in Type 2 Diabetes: A Multiethnic Asian Study and Meta-Analysis |
Q47243282 | Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease |
Q89878202 | Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations |
Search more.